Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy

Summary

Johnson & Johnson is highlighted as a dividend aristocrat stock with focus on cancer and neuroscience therapeutic areas. No specific catalysts, clinical data, or financial information is provided in this brief portfolio commentary.